Estimating cervical precancer and cancer risk based on HPV testing, cervical cytology and colposcopic impression: results from the ESTAMPA multicentric study in Latin America

Background Cervical cancer is largely preventable, yet major gaps persist in detection and timely management of cervical precancer, particularly in low- and middle-income countries. Using data from the ESTAMPA multicentric study, we derived stratified absolute risk estimates for cervical precancer and cancer based on HPV testing, cervical cytology, and colposcopic impression. Methods ESTAMPA is a multicenter cervical cancer screening study (NCT01881659) that recruited women aged 30–64 years across 12 centres, comprising primary and secondary care facilities, hospitals, laboratories, and universities, across nine Latin American countries: Argentina, Bolivia, Colombia, Costa Rica, Honduras, Mexico, Paraguay, Peru, and Uruguay. The aims of the study were (1) to investigate the performance of emerging cervical cancer screening and triage techniques among women 30 years and older and (2) to evaluate the feasibility of different approaches for implementation of organised HPV-based screening programmes. Women were screened with HPV testing and cervical cytology. Those with positive screening results were referred to colposcopy using a standardised protocol including colposcopic impression, directed biopsies, and treatment as indicated. Women with normal colposcopy or histology less than CIN2 were recalled after 18 months for repeat HPV testing and colposcopy if HPV-positive. Absolute risks of histologically confirmed CIN3+ detected at baseline or follow-up were estimated integrating HPV testing, cytology, and colposcopic impression. Findings Between December 12, 2012, and August 31, 2022, 44,135 women with a valid HPV test were included, of whom 6236 (14.1%) were HPV-positive. Overall, 764 CIN3+ lesions were detected (1.73%; 95% CI 1.61–1.86). CIN3+ risk was 12.0% (747/6236; 95% CI 11.2–12.8) among HPV-positive women compared with 0.04% (17/37,899; 95% CI 0.03–0.07) among HPV-negative women. Among HPV-positive women, risk increased with cervical cytological severity, reaching 62.9% (95% CI 57.1–68.5) for HSIL+, 22.4% (95% CI 18.4–26.8) for LSIL, and 19.1% (95% CI 15.1–23.6) for ASC-US; a positive colposcopic impression further increased CIN3+ risk to 70.2% (95% CI 64.1–75.9), 28.5% (95% CI 23.5–34.0), and 24.5% (95% CI 19.4–30.2), respectively. Among HPV16/18-positive women, CIN3+ risk was 32.8% (95% CI 28.9–37.0) increasing to 46.2% (95% CI 40.8–51.6) when abnormal colposcopy was present. Interpretation We confirmed a high underlying risk of CIN3+ in the Latin American population, with risk strongly stratified by HPV positivity, increasing cervical cytological severity, and positive colposcopic impression. These estimates may support WHO-aligned cervical screening and risk-based management strategies in LMICs and contribute to accelerating cervical cancer elimination. Funding International Agency for Research on Cancer (IARC/WHO); UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP/WHO); Pan American Health Organization (PAHO); US National Cancer Institute (NCI); NCI Center for Global Health; National Agency for the Promotion of Research, Technological Development and Innovation and National Cancer Institute of Argentina; National Cancer Institute of Colombia; Costa Rican Social Security Fund (CCSS); National Council for Science and Technology (CONACYT), Paraguay; and other local funders.

Authors

Institutions

Publication Details

Journal
The Lancet Regional Health - Americas
Published
2026-11-14
DOI
https://doi.org/10.1016/j.lana.2026.101685
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Estimating cervical precancer and cancer risk based on HPV testing, cervical cytology and colposcopic impression: results from the ESTAMPA multicentric study in Latin America

Joan Valls, Gino Venegas, Natalia Pérez, Diana Giménez et al.
The Lancet Regional Health - Americas
Cervical Cancer and HPV Research
article

Estimating cervical precancer and cancer risk based on HPV testing, cervical cytology and colposcopic impression: results from the ESTAMPA multicentric study in Latin America

Joan Valls, Gino Venegas, Natalia Pérez, Diana Giménez, Laura Alicia Fleider, Marcela Celis, Julio Yamil Jiménez, María Liz Bobadilla, Ana María Soilán, Oscar Lora, José Jerónimo, Jorge Luis Santin, Jacqueline Figueroa, Margarita M Rodríguez de la Peña, Marina Ortega, Josefina Martínez-Better, Andrea Verónica Beracochea, Elmer Turcios, Mauricio González, Alex Montoya, Gabriela Natalia Kaznowiecki, Carlos Sosa
article en

Abstract

Background Cervical cancer is largely preventable, yet major gaps persist in detection and timely management of cervical precancer, particularly in low- and middle-income countries. Using data from the ESTAMPA multicentric study, we derived stratified absolute risk estimates for cervical precancer and cancer based on HPV testing, cervical cytology, and colposcopic impression. Methods ESTAMPA is a multicenter cervical cancer screening study (NCT01881659) that recruited women aged 30–64 years across 12 centres, comprising primary and secondary care facilities, hospitals, laboratories, and universities, across nine Latin American countries: Argentina, Bolivia, Colombia, Costa Rica, Honduras, Mexico, Paraguay, Peru, and Uruguay. The aims of the study were (1) to investigate the performance of emerging cervical cancer screening and triage techniques among women 30 years and older and (2) to evaluate the feasibility of different approaches for implementation of organised HPV-based screening programmes. Women were screened with HPV testing and cervical cytology. Those with positive screening results were referred to colposcopy using a standardised protocol including colposcopic impression, directed biopsies, and treatment as indicated. Women with normal colposcopy or histology less than CIN2 were recalled after 18 months for repeat HPV testing and colposcopy if HPV-positive. Absolute risks of histologically confirmed CIN3+ detected at baseline or follow-up were estimated integrating HPV testing, cytology, and colposcopic impression. Findings Between December 12, 2012, and August 31, 2022, 44,135 women with a valid HPV test were included, of whom 6236 (14.1%) were HPV-positive. Overall, 764 CIN3+ lesions were detected (1.73%; 95% CI 1.61–1.86). CIN3+ risk was 12.0% (747/6236; 95% CI 11.2–12.8) among HPV-positive women compared with 0.04% (17/37,899; 95% CI 0.03–0.07) among HPV-negative women. Among HPV-positive women, risk increased with cervical cytological severity, reaching 62.9% (95% CI 57.1–68.5) for HSIL+, 22.4% (95% CI 18.4–26.8) for LSIL, and 19.1% (95% CI 15.1–23.6) for ASC-US; a positive colposcopic impression further increased CIN3+ risk to 70.2% (95% CI 64.1–75.9), 28.5% (95% CI 23.5–34.0), and 24.5% (95% CI 19.4–30.2), respectively. Among HPV16/18-positive women, CIN3+ risk was 32.8% (95% CI 28.9–37.0) increasing to 46.2% (95% CI 40.8–51.6) when abnormal colposcopy was present. Interpretation We confirmed a high underlying risk of CIN3+ in the Latin American population, with risk strongly stratified by HPV positivity, increasing cervical cytological severity, and positive colposcopic impression. These estimates may support WHO-aligned cervical screening and risk-based management strategies in LMICs and contribute to accelerating cervical cancer elimination. Funding International Agency for Research on Cancer (IARC/WHO); UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP/WHO); Pan American Health Organization (PAHO); US National Cancer Institute (NCI); NCI Center for Global Health; National Agency for the Promotion of Research, Technological Development and Innovation and National Cancer Institute of Argentina; National Cancer Institute of Colombia; Costa Rican Social Security Fund (CCSS); National Council for Science and Technology (CONACYT), Paraguay; and other local funders.

The Lancet Regional Health - AmericasVol. 66
Universitat de Lleida (ES), University of Piura (PE), National Autonomous University of Honduras (HN), University of California, San Francisco (US), University of Puerto Rico System (PR), Pontificia Universidad Javeriana (CO), Karolinska Institutet (SE), Costa Rican Department of Social Security (CR), Central American Technological University (HN), Universidad de Antioquia (CO), World Health Organization Regional Office for the Americas (US), Liga Contra el Cancer (PE), Fundación Valle del Lili (CO), Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud (CR), World Health Organization (CH), Administración Nacional de Laboratorios e Institutos de Salud (AR), Instituto Nacional de Cancerología (CO), Hospital de Clínicas "José de San Martín" (AR), University of Saint Francis Xavier (BO), Instituto Nacional de Salud Pública (MX), Fundación Santa Fe de Bogotá (CO), Instituto de Investigación Biomédica de Lleida (ES), Ministerio de Salud Pública y Bienestar Social (PY), National Cancer Institute (US), Comisión Honoraria de Lucha contra el cáncer (UY), Hospital Posadas (AR), Hospital de Clínicas (UY), Centre international de recherche sur le cancer (FR), Centro Medico Nacional - Hospital Nacional (PY), Hospital General San Felipe (HN), Universidad Nacional de Asunción (PY)
Good health and well-being
Cervical Cancer and HPV Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon